CHOCO-diet: Dark Chocolate, Cholesterol and Microbiota

Sponsor
University of Bari (Other)
Overall Status
Unknown status
CT.gov ID
NCT03850405
Collaborator
(none)
40
1
2
10
4

Study Details

Study Description

Brief Summary

Scientific evidence shows that a major consume of flavonoids is associated with a minor risk of coronary disease and a modification of the gut microbiome profile.

Dark chocolate has a major quantity of flavonoids by weight in comparison to wine, dark tea, blueberry juice, apples and, in particular the flavanols (i.e. catechin, epicatechin and procyanidin) can have protective and metabolic effects with reduction of the insulin resistance and improvement of the endothelial function in adults.

In line with the aforementioned evidence, the present study has the aim of analyze the effect of dark chocolate (70%) on cardiovascular risk and on the metabolism in a population with mild dyslipidemia.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Dark Chocolate
N/A

Detailed Description

Chocolate, the main product deriving from cocoa beans (Theobroma cacao, from the Greek "food of the gods") has its origin in Mexico, where Maya, Inca and Aztecs practiced their cultivation. For centuries, it has been appreciated for its pleasant taste and for its beneficial effects on health, and it is one of the most sought-after worldwide, with a consumption greatly increasing in recent years thanks to a wide availability of products on the market.

Dietary choices are strongly influenced by the taste and consistency of foods. Fat is largely responsible for the sensory properties of many foods and, therefore, contribute greatly to the pleasure of eating. Dark chocolate consists of ≈43% of lipids, mainly represented by cocoa butter, the latter consisting on average of 33% of oleic acid, 25% of palmitic acid and 33% of stearic acid. Another component of chocolate is polyphenols, in particular flavonoids, substances with numerous beneficial effects for health, including antihypertensive, anti-inflammatory, antithrombotic, metabolic and prebiotic activity, playing a role in the change of human intestinal microbiota.

Recent scientific studies show an inverse correlation between flavonoid intake in the diet and the incidence of diabetes, such as to hypothesize the use of flavonoid-rich foods as potential nutritional supplements in the management of diabetes. The cocoa flavonoids can bring benefits to the insulin-resistance condition by improving endothelial function, modifying glucose metabolism and reducing oxidative stress, which is considered the main cause of insulin resistance. In healthy individuals and patients with moderate cardiovascular risk, regular flavonoid intake improves levels of cardiovascular biomarkers, lowering serum LDL cholesterol and triglycerides and increasing HDL cholesterol. The flavonoids present in cocoa can also inhibit platelet aggregation by down-regulation of the cellular synthesis of eicosanoids.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Dark Chocolate on Gut Microbiome and Cholesterol Reduction in Subjects With Moderate Dyslipidemia
Anticipated Study Start Date :
May 1, 2019
Anticipated Primary Completion Date :
Jul 1, 2019
Anticipated Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chocolate

20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day

Dietary Supplement: Dark Chocolate
20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.

No Intervention: Control

20 patients (matched per gender) undergoing a low-fat dietary regimen

Outcome Measures

Primary Outcome Measures

  1. Total Cholesterol [Baseline]

    Total cholesterol in mg/100ml will be measured by serum extraction from 3ml of whole peripheral blood.

  2. Triglycerides [Baseline]

    Triglycerides in mg/dl will be measured by serum extraction from 3ml of whole peripheral blood.

  3. HDL Cholesterol [Baseline]

    HDL Cholesterol in mg/dl will be measured by serum extraction from 3ml of whole peripheral blood.

  4. Counts of viable fecal bacterial cells [Baseline]

    Estimate of microbial Shannon's (H') diversity from 3g faecal sample: Heterotrophic aerobic and anaerobic bacteria Total anaerobes Lactic acid bacteria Lactobacillus Lactococcus and Streptococcus Staphylococcus Bacteroides Porphyromonas and Prevotella Enterobacteria Aeromonas and Pseudomonas Bifidobacterium Enterococci

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Individuals able to fill an Informed Consent

  • Aged 40-60 years old with 1:1 matched criteria, age difference of ± 1 year old

  • Patients with mild dyslipidemia (total cholesterol 201-250 mg/dL, LDL≥155 mg/dL) with or without hypertriglyceridemia (150-180 mg/dL) who accept to be inserted in a program aimed to reduce their caloric intake, including diet alone or diet plus chocolate

Exclusion Criteria:
  • Missing Informed Consent

  • Diagnosis of organic diseases, including neoplastic inflammatory diseases or cardiovascular diseases

  • Patients on statin therapy

  • Drugs which can affect the gastrointestinal tract and interfere with the symptoms

  • Pregnancy

  • Presence of diseases with a prognosis of less than 12 months

  • Hypersensitivity to chocolate or chocolate components

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Biomedical Sciences Human Oncology - Clinica Medica "A. Murri" Bari BA Italy 70124

Sponsors and Collaborators

  • University of Bari

Investigators

  • Principal Investigator: Piero Portincasa, MD, PhD, Clinica Medica "A. Murri", DIMO - University of Bari

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
piero portincasa, Professor of Medicine, Head Division of Internal Medicine, University of Bari
ClinicalTrials.gov Identifier:
NCT03850405
Other Study ID Numbers:
  • 1419UO
First Posted:
Feb 21, 2019
Last Update Posted:
Apr 17, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 17, 2019